Paul Fernyhough
Degrees, Title/Position:
BSc PhD
Professor and Head, Department of Pharmacology & Therapeutics; Professor, Department of Physiology & Pathophysiology, University of Manitoba
Director, Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research
Goal Groups/Integration Themes:
Clinical Trials & New Therapies
Description:
There is no FDA-approved treatment for diabetic neuropathy, a condition that afflicts half of the 27 million North Americans who suffer from diabetes. The neurodegeneration seen in diabetes leads to sensory fiber depletion and loss of protective sensation – a primary trigger of the diabetic foot and lower limb amputation. With financial support from several key stakeholders in the field of diabetes, a small start-up company, WinSanTor Inc, was established in 2012 and is developing a proprietary first-in-class therapy to prevent and reverse nerve damage. The SPOR network is performing phase 2 clinical trials with novel topical therapeutics provided by WinSanTor. In the USA the FDA is currently assessing this therapeutic approach for classification as an investigational new drug (IND).
PubMed Link:
Home Page/Departmental Page:
Dr. Paul Fernyhough, Neurodegeneration Lab | St. Boniface Hospital Research<http://www.sbrc.ca/fernyhough/